App-Quantinova.ai

A multi OMICS approach to generate novel mechanistic insights and new targets for cardiovascular regeneration in the ischaemic adult heart

Ziwen Li - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Becaplermin

The regulation of human brown adipose tissue

Roland Stimson - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Obesity

Glucocorticoid

Management of primary hyperparathyroidism (PHPT)

Neil Gittoes - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Secondary hyperparathyroidism

N/A

Type 1 diabetes remission: who, how and when

Paolo Pozzilli - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

DLK1 expressing cells mark a population of progenitor cells in the adrenal cortex and contribute to the zonation of the adrenal gland

Katia Mariniello - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Dexamethasone

Real world prospective application of ATA guidelines in over 500 aspirated thyroid nodules: Is it time for changing the size cut-offs for FNA?

Stamatina Ioakim - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Thyroid nodules

N/A

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

Mnica R Gadelha - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Neuroendocrine tumors

Somatostatin

Pdgfrα-driven Alms1 deletion in mice recapitulates the obesity and insulin resistance of Alms1 global knockout

Eleanor McKay - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Body composition during childhood, adolescence and adulthood influences the odds of developing polycystic ovary syndrome: a mendelian randomisation study with a systematic review and meta-analysis

Laurence J Dobbie - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Polycystic Ovary Syndrome

N/A

The glucocorticoid transporter ATP-binding cassette subfamily C member 1 (ABCC1) influences adiposity, glucose homeostasis and insulin sensitivity in male mice

Elisa Villalobos - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Glucocorticoid

Kisspeptin administration has therapeutic potential for men with low sexual desire by increasing penile tumescence and sexual brain processing

Edouard Mills - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

A tumor-borne Angpt2/Tie2 autostimulatory loop controls tumorigenesis

Natalia Pellegata - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Trebananib

The European Registries for Rare Endocrine Conditions (EuRRECa): the use of a core registry for collecting common data elements and clinician and patient reported outcomes

Ana Luisa Priego Zurita - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of patients with primary hyperaldosteronism

Kerstin Sander - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary aldosteronism

N/A

11-oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing’s disease

Hanna Nowotny - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cushing's syndrome

DHEA-S

Classic and 11-oxygenated androgens in serum and saliva across adulthood and the menstrual cycle – a mass spectrometry-based cross-sectional study

Punith Kempegowda - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

DHEA-S

Discovery of microRNA biomarkers in circulation and bone tissue from a type-2 diabetes mellitus rat model under different anti-osteoporotic treatments

David Carro Vzquez - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Type 2 diabetes mellitus

N/A

Single-nuclei transcriptome of adult human adrenal glands reveals novel insights into molecular mechanisms intrinsic to adrenocortical tumourigenesis and cortisol secretion

Barbara Altieri - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Radiotherapy for adults with pituitary adenoma or craniopharyngioma is associated with increased risk of second brain tumour : A multi-centre study of 3,613 patients with long-term imaging surveillance

Ross Hamblin - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pituitary adenomas

N/A

AKR1D1 knockdown identifies 7α-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA) as a driver of metabolic dysfunction and hepatocellular cancer risk in patients with non-alcoholic fatty liver disease (NAFLD)

Nikolaos Nikolaou - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nonalcoholic fatty liver disease

N/A

Filters

45280 Abstracts